Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398

Cancer Letters

Volumn 208, Issue 1, 2004, Pages 115-122

  Obara, Soichi ^a   Nakata, Masanori ^b   Takeshima, Hideo ^a   Katagiri, Hideki ^c   Asano, Tomoichiro ^d   Oka, Yoshitomo ^c   Maruyama, Ikuro ^a   Kuratsu, Jun Ichi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Glioblastoma; ILK; NS 398; PKB Akt Serine 473; PTEN

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; INTEGRIN LINKED KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

BRAIN; BRAIN NEOPLASMS; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MEMBRANE PROTEINS; NITROBENZENES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 11144227278     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.11.020     Document Type: Article

References (37)

1. Kreth F.W., Warnke P.C., Scheremet R., Ostertag C.B. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J. Neurosurg. 78:1993;762-766.
2. Kreth F.W., Berlis A., Spiropoulou V., Faist M., Scheremet R., Rossner R., et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer. 86:1999;2117-2123.
3. Lyden D.C., Mason W.P., Finlay J.L. The expanding role of chemotherapy for pediatric supratentorial malignant gliomas. J. Neurooncol. 28:1996;185-191.
4. Trask T.W., Trask R.P., Aguilar-Cordova E., Shine H.D., Wyde P.R., Goodman J.C., et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1:2000;195-203.
5. Li D.M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57:1997;2124-2129.
6. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
7. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
8. Rasheed B.K., Stenzel T.T., McLendon R.E., Parsons R., Friedman A.H., Friedman H.S., et al. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57:1997;4187-4190.
9. Liu W., James C.D., Frederick L., Alderete B.E., Jenkins R.B. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 57:1997;5254-5257.
10. Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57:1997;3660-3663.
11. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57:1997;4997-5000.
12. Teng D.H., Hu R., Lin H., Davis T., Iliev D., Frye C., et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57:1997;5221-5225.
13. Kohno T., Takahashi M., Manda R., Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer. 22:1998;152-156.
14. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
15. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl Acad. Sci. USA. 96:1999;6199-6204.
16. Ramaswamy S., Nakamura N., Vazquez F., Batt D.B., Perera S., Roberts T.M., Sellers W.R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA. 96:1999;2110-2115.
17. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
18. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:1999;857-868.
19. Hannigan G.E., Leung-Hagesteijn C., Fitz-Gibbon L., Coppolino M.G., Radeva G., Filmus J., et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 379:1996;91-96.
20. Attwell S., Roskelley C., Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene. 19:2000;3811-3815.
21. Troussard A.A., Costello P., Yoganathan T.N., Kumagai S., Roskelley C.D., Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene. 19:2000;5444-5452.
22. Delcommenne M., Tan C., Gray V., Rue L., Woodgett J., Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl Acad. Sci. USA. 95:1998;11211-11216.
23. Persad S., Attwell S., Gray V., Mawji N., Deng J.T., Leung D., et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 276:2001;27462-27469.
24. Persad S., Attwell S., Gray V., Delcommenne M., Troussard A., Sanghera J., Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. USA. 97:2000;3207-3212.
25. Marotta A., Tan C., Gray V., Malik S., Gallinger S., Sanghera J., et al. Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 20:2001;6250-6257.
26. Kuratsu J., Sato K., Saitoh Y., Takeshima H., Morioka M., Ushio Y. The mechanism of growth-regulation of glioma cells by trapidil. J. Neurooncol. 23:1995;201-206.
27. Ono H., Katagiri H., Funaki M., Anai M., Inukai K., Fukushima Y., et al. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol. Endocrinol. 15:2001;1411-1422.
28. Kitajima I., Kawahara K., Hanyu N., Shin H., Tokioka T., Soejima Y., et al. Enhanced E-cadherin expression and increased calcium-dependent cell-cell adhesion in human T-cell leukemia virus type I Tax-expressing PC12 cells. J. Cell Sci. 109:(Pt3):1996;609-617.
29. Li F., Zhang Y., Wu C. Integrin-linked kinase is localized to cell-matrix focal adhesions but not cell-cell adhesion sites and the focal adhesion localization of integrin-linked kinase is regulated by the PINCH-binding ANK repeats. J. Cell Sci. 112:(Pt 24):1999;4589-4599.
30. Wang S.C., Makino K., Xia W., Kim J.S., Im S.A., Peng H., et al. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene. 20:2001;6960-6964.
31. Hannigan G.E., Bayani J., Weksberg R., Beatty B., Pandita A., Dedhar S., Squire J. Mapping of the gene encoding the integrin-linked kinase, ILK, to human chromosome 11 p15.5-p15.4. Genomics. 42:1997;177-179.
32. Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 280:1998;1614-1617.
33. Lin H., Bondy M.L., Langford L.A., Hess K.R., Delclos G.L., Wu X., et al. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin. Cancer Res. 4:1998;2447-2454.
34. Radeva G., Petrocelli T., Behrend E., Leung-Hagesteijn C., Filmus J., Slingerland J., Dedhar S. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J. Biol. Chem. 272:1997;13937-13944.
35. White D.E., Cardiff R.D., Dedhar S., Muller W.J. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene. 20:2001;7064-7072.
36. Shono T., Tofilon P.J., Bruner J.M., Owolabi O., Lang F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61:2001;4375-4381.
37. Joki T., Heese O., Nikas D.C., Bello L., Zhang J., Kraeft S.K., et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60:2000;4926-4931.